| Document |
Document Title |
|
WO/2022/065413A1 |
The present invention addresses the problem of providing a novel artificial nucleic acid, a method for producing the same, and a use thereof. The problem can be solved by an artificial nucleic acid having a unit derived from a compound r...
|
|
WO/2022/058312A1 |
A method of producing 1,4-dihydronicotinamide riboside (NRH) is disclosed. The method comprises providing nicotinamide riboside chloride (NRCl) in a liquid solution; adding a metal dithionite into the liquid solution under a first temper...
|
|
WO/2022/053576A1 |
The present invention relates to a new class of compounds based on a hexose featuring at least two 6-fluorides. The class is useful as inhibitors of 4,6-dehydratase enzymes. Such inhibitors are suitable for use as a medicament, for examp...
|
|
WO/2022/048680A1 |
Provided is a method for preparing adenosine. The method comprises subjecting adenylic acid to a hydrolysis reaction in a protic solvent under an acidic buffer system. Also provided is a method for purifying adenosine. The method compris...
|
|
WO/2022/043531A1 |
The present disclosure relates to ethylene-bridged nucleic acid (ENA) compounds, which may find use in therapy and/or prophylaxis. These ENA compounds may also find use as building blocks for preparing oligonucleotides, said oligonucleot...
|
|
WO/2022/047182A1 |
The current disclosure provides use of high dose nicotinamide adenine dinucleotide (NAD) precursor regimens for reduction of inflammation in human patients with preexisting inflammation. The NAD precursor can be nicotinamide riboside (NR...
|
|
WO/2022/046910A1 |
Prodrugs of 6-mercaptopurine (6-MP) and methods of their use for treating cancers and autoimmune diseases are disclosed.
|
|
WO/2022/040473A1 |
The present invention provides stereoselective processes of manufacture for the phosphoramidate nucleotide Compound 1 or a pharmaceutically acceptable salt thereof.
|
|
WO/2022/038632A1 |
The present invention discloses novel nigericin derivatives of general formula (I) that exhibit low toxicity and inhibition activity against gram-positive bacteria, gram-negative bacteria, and viruses. The present invention also disclose...
|
|
WO/2022/040301A1 |
Various nucleoside phosphate and phosphonate analogues are provided for treatment of viral infections. Methods of preparing the analogues, pharmaceutical compositions containing the analogues, and methods of using the analogues as antivi...
|
|
WO/2022/035852A1 |
Novel N 4 -substituted decitabine analogs are disclosed that exhibit promising in vitro and in vivo therapeutic activity. These novel compounds were shown to be resistant to deamination via cytidine deaminase (CDA) metabolism and provide...
|
|
WO/2022/033589A1 |
The present invention relates to a new crystal form of β-nicotinamide mononucleotide represented by formula (I) and a preparation method therefor. The method of the present invention does not use toxic and harmful organic solvents such ...
|
|
WO/2022/031150A1 |
The present invention provides a conjugate including: cell-membrane-permeable deoxycytidine activated in a triphosphate form in a cell; and a silyl ether-containing linker of which one end is linked to a hydroxyl group of a drug, wherein...
|
|
WO/2022/022472A1 |
Use of a nicotinamide nucleoside triaryl formate compound and a composition thereof in increasing the level of coenzyme I (NAD) in a human body, improving a health condition or treating a related disease, and a compound of formula (II-1)...
|
|
WO/2022/026533A1 |
Embodiments of the present disclosure provide compositions and methods for performing positron emission tomography (PET) and, more particularly, to compositions and methods for the development and use of 18F-based PET tracers for use in ...
|
|
WO/2022/019836A1 |
Disclosed herein include methods and compositions for nucleic acid synthesis using a terminal deoxynucleotidyl transferase with deoxyribonucleotide trisphosphates each comprising a modified base with a photocleavable carbon chain moiety ...
|
|
WO/2022/008025A1 |
Disclosed herein are nucleosides and nucleotides analogs, methods for preparing the same, and methods for treating and/or ameliorating infection caused by a Coronaviridae virus, a Caliciviridae virus, an Orthomyxoviridae virus, a Herpesv...
|
|
WO/2021/195533A9 |
This disclosure relates to the synthesis of novel modified oligonucleotides. The synthesis of novel phosphoramidites are also provided.
|
|
WO/2022/004388A1 |
Disclosed are a bridged nucleoside and a nucleotide using the same. The nucleoside according to the present invention is represented by formula (I). The bridged nucleoside of the present invention is usable as a substitute for a phosphor...
|
|
WO/2022/000087A1 |
It is provided the synthesis of an aptamer-like encoded oligomer (ALEnOmer), method of producing same and method of preparing a library of ALEnOmes. More particularly, the method of preparing ALEnOmer comprises coupling at least one phos...
|
|
WO/2022/006231A1 |
Provided herein are compounds and methods of using these compounds to treat disorders related to DPAGT1 function, including cancer and bacterial infections.
|
|
WO/2021/261062A1 |
Provided is an aqueous solution having, dissolved therein, 0.3 to 200 mM of a stilbene compound (A) that is a compound represented by formula (1) or a glycoside thereof and 0.3 to 200 mM of a flavin derivative (B) selected from riboflavi...
|
|
WO/2021/260107A1 |
This specification discloses a novel methodology for labelling RNA via enzymatic incorporation of a minimally perturbing fluorescent tricyclic cytosine analogue. This analogue is shown to be 100% incorporated in example transcripts and i...
|
|
WO/2021/259881A1 |
The present invention concerns a nucleoside or nucleotide comprising a nucleobase attached to a detectable label via a cleavable linker, wherein the nucleoside or nucleotide comprises a ribose or 2' deoxyribose moiety and a 3'-OH blockin...
|
|
WO/2021/262786A1 |
The disclosure relates, in certain aspects, to the discovery of certain compounds that are useful to treat and/or prevent fungal infections in a subject. The disclosure further relates, in certain aspects, to the discovery of certain com...
|
|
WO/2021/253362A1 |
A method for preparing nicotinamide mononucleotide by using nicotinamide as a raw material, the method comprising: in a solvent of acetonitrile, dichloromethane, 1,2-dichloroethane or a liquid sulfur dioxide, catalyzing the reaction of n...
|
|
WO/2021/257569A1 |
The present disclosure relates to compounds and compositions for use in treating disease, such as viral infection. As disclosed herein, the compounds include an "NMN-like" moiety linked to another moiety with biological activity upon adm...
|
|
WO/2021/256297A1 |
[Problem] To provide: a bridged nucleoside which is not likely to be degraded by nuclease in vivo, while having high binding affinity and specificity to target mRNA and being capable of efficiently controlling the expression of a specifi...
|
|
WO/2021/257643A1 |
Crystalline forms of the compound of Formula (I), which modulates the conversion of AMP to adenosine by 5'-nucleotidase, and compositions containing the compound and methods for preparing the crystalline forms, are described herein. The ...
|
|
WO/2021/250443A1 |
The present application relates to spreadable, margarine-type products with a fat content of between 58% and 70%, which use natural flavouring techniques together with crystallisation processes to reduce the sodium content by between 40%...
|
|
WO/2021/236208A1 |
Provided is a method of treating a disease caused by a nidovirus that encodes Nsp15, such as a coronavirus, an arterivirus, or a torovirus, in a subject in need thereof comprising administering a therapeutically effective amount of an ac...
|
|
WO/2021/232719A1 |
A conjugate containing an α-galactosyl ceramide analogue and a carbohydrate antigen and a preparation method therefor and a use thereof, belonging to the technical field of antitumor carbohydrate vaccine development. Provided is the con...
|
|
WO/2021/234532A1 |
The present invention relates to a pharmaceutical formulation of 5-fluoropyrimidine derivatives or a salt, solvate, or hydrate thereof for oral administration wherein the formulation is a simple composition for ingestion, simple, safest,...
|
|
WO/2021/231324A1 |
Many regions of genomic DNA are highly similar to other regions of the genome and thus are very difficult to capture without also capturing the similar, undesired regions. This leads to over-sequencing of regions for which there is no in...
|
|
WO/2021/226521A1 |
Treatments for SARS-CoV-2 infection, COVID-19, symptoms of COVID-19, and similar infections. Specifically, treatments for patients identified as having Acute Respiratory Distress Syndrome (ARDS), and specifically COVID-19 ARDS, and/or su...
|
|
WO/2021/226629A1 |
The present disclosure provides compounds of Formula (I), useful for the activation of Triggering Receptor Expressed on Myeloid Cells 2 ("TREM2"). This disclosure also provides pharmaceutical compositions comprising the compounds, uses o...
|
|
WO/2021/223398A1 |
Provided in the present invention is a crystal form for treating a liver disease of tenofovir phosphate(9-[(2R)-2-[(2R,4S)-4-(3-chlorophenyl)-2-oxo-1,3,2-
dioxaphosphorinane-2-methoxy]propyl]adenine fumarate), paladovir mesylate((+)-cis-...
|
|
WO/2021/226327A1 |
Disclosed herein, inter alia, are compounds, compositions, and methods of use thereof for sequencing a nucleic acid.
|
|
WO/2021/217685A1 |
A six-membered ring-containing nucleoside compound 7 and a preparation method therefor. The structural formula of the compound 7 is (I), wherein R1 is selected from one of (II), (III), (IV), and (V), and R2 is hydroxyl or alkynyl.
|
|
WO/2021/216998A1 |
Disclosed herein, inter alia, are compounds, modified nucleotides, compositions, and methods of using the same.
|
|
WO/2021/216722A1 |
The present invention provides stereoselective processes of manufacture for the phosphoramidate nucleotide Compound 1 or a pharmaceutically acceptable salt thereof.
|
|
WO/2021/216940A1 |
A method of producing a triazoline-containing compound, the method comprising reacting an alkene, which comprises at least one a C=C double bond, with an azido compound, which comprises an azide anion having the chemical formula N3 -, wh...
|
|
WO/2021/214299A1 |
The present invention relates to Nicotinamide mononucleotide derivatives of formula (I) or (Ia) for use in the treatment and/or prevention of viral infections, such as respiratory infections. The present invention further relates to phar...
|
|
WO/2021/211890A1 |
In one aspect, the disclosure relates to pharmaceutical compositions comprising 2'-deoxycytidine analogs, oral and other dosage formulations containing the same, and methods of making the same. In another aspect, the disclosure relates t...
|
|
WO/2021/211759A1 |
Disclosed herein are methods, compositions and kits for treating and inhibiting Poxviridae virus infections, for example, Vaccinia virus infections. Further disclosed are stop- gap methods for controlling the spread of Poxviridae virus i...
|
|
WO/2021/203409A1 |
A novel non-hygroscopic low-variability crystalline form for treatment of hepatitis C. The novel crystalline form T has a simple crystallization process, is easy for industrial production, and has no hygroscopicity. The use of a suitable...
|
|
WO/2021/196105A1 |
The present invention relates to the field of medicines, in particular to an anti-tumor effective component of Hedyotis diffusa, a preparation method therefor and the use thereof. Provided in the present invention is the use of one or a ...
|
|
WO/2021/202907A2 |
The present invention relates to methods, compounds, and compositions for treating viral infections, including COVID-19 viral infections. In certain embodiments, the compositions comprise: i) a remdesivir analog, ii) remdesivir or a remd...
|
|
WO/2021/202788A2 |
The present disclosure provides oligomeric compounds comprising a modified oligonucleotide having at least one stereo-non-standard 4' -thio nucleoside.
|
|
WO/2021/198958A1 |
A nucleic acid polymer comprising 8 to 50 nucleoside subunits linked by intersubunit linkages, wherein the nucleic acid polymer comprises (A) one or more 3'-5' thiophosphoramidate intersubunit linkage and the remaining intersubunit linka...
|
